Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
0166+NBP
- Development stage
- Preclinical
- Lead developer
- AlaMab Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
0166+NBP is a preclinical combination therapy being developed by AlaMab Therapeutics (a subsidiary of CSPC Pharmaceutical Group) for the treatment of stroke. The combination consists of ALMB-0166, a humanized monoclonal antibody antagonist targeting Connexin43 (Cx43) hemichannels, and NBP (butylphthalide or 3-n-butylphthalide), a small molecule neuroprotective agent. ALMB-0166 works by blocking Connexin43 hemichannels on astrocytes, thereby preventing the release of neurotoxic molecules such as ATP and glutamate, reducing neuroinflammation and glial scar formation. NBP provides complementary neuroprotective effects by reconstructing microcirculation, protecting mitochondrial function, and inhibiting neuronal apoptosis and oxidative stress. Together, the combination aims to synergistically alleviate ischemic brain injury and improve neurological recovery following a stroke.
- Other names
- ALMB-0166 + 3-n-butylphthalideALMB-0166 + NBPALMB-0166 + butylphthalide
02
Targets
GJA1 (Connexin43 Hemichannel)
Beyond the preview
Go deeper on 0166+NBP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 0166+NBP.